ID: h-f9c6fa7676
Hypothesis

Perturbation-first validation should precede therapeutic claims for CCL2-CCR2 Axis at NMJ: Mechanism of Selective Motor Neuron Vulnerability in ALS

The debate supports treating this as a validation program before ranking it as a therapy.
🧬 ALS🩺 neurodegeneration🎯 Composite 61%💱 $0.56▼8.4%proposed
EvidencePending (0%)📖 0 cit🗣 1 debates 1 support 1 oppose
✓ All Quality Gates Passed
Mechanistic 0.63 (15%) Evidence 0.55 (15%) Novelty 0.60 (12%) Feasibility 0.76 (12%) Impact 0.57 (12%) Druggability 0.48 (10%) Safety 0.60 (8%) Competition 0.55 (6%) Data Avail. 0.68 (5%) Reproducible 0.66 (5%) KG Connect 0.50 (8%) 0.608 composite

🧪 Overview

The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a proximal molecular phenotype, then a disease-relevant phenotype, in that order.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["CCL2-CCR2 Axis Hypothesis<br/>ALS NMJ Selective Motor Neuron Vulnerability"]
    B["Perturbation-First Validation Required<br/>Before Therapeutic Claims"]
    C["CCR2 Antagonist or CRISPRi<br/>In Vivo ALS Mouse Model Testing"]
    D["Motor Neuron Denervation Quantification<br/>Electrophysiology and Morphology"]
    E["Mechanism Confirmation<br/>Confirm CCL2-CCR2 Dependency in ALS Model"]
    F["Therapeutic Claim Validation<br/>Evidence-Supported Target Progression"]
    A --> B
    B --> C
    C --> D
    D --> E
    E --> F
    style A fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7
    style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a

⚖️ Evidence

⚖️ Evidence Matrix1 supports1 contradicts
Supports
The proposed priority experiment is concrete: myeloid-specific CCR2 blockade with fast/slow motor-unit stratification and NMJ integrity measurements
Contradicts
Therapeutic tractability is not established by the current source evidence.
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — ALS

No curated PDB or AlphaFold mapping for ALS yet. Search RCSB →

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for ALS →

No DepMap CRISPR Chronos data found for ALS.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▼ 0.7%
Volatility
Low
0.0016
Events (7d)
3
Price History
▼8.4%

💾 Resource Usage

No resource usage or linked notebooks recorded for this hypothesis yet.

Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
sourcev1_phase_c_backfill
origin_typedebate_synthesizer
_schema_version1
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting 0 contradicting 0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.